A pilot study of nedaplatin and etoposide for recurrent gynecological malignancies

Oncology Reports

Volumn 5, Issue 4, 1998, Pages 881-884

  Adachi, Susumu ^a   Ogasawara, Toshitada ^a   Yamasaki, Noriyuki ^a   Shibahara, Hiroaki ^a   Tsuji, Yoshiyuki ^a   Takemura, Tadashi ^a   Koyama, Koji ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Cisplatin; Combination chemotherapy; Gynecological malignancy; Nedaplatin

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; NEDAPLATIN; SEROTONIN 3 ANTAGONIST;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; ENDOMETRIUM CANCER; FEMALE; GASTROINTESTINAL TOXICITY; GYNECOLOGIC CANCER; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; LEUKOPENIA; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; UTERINE CERVIX CANCER;

EID: 0031838825     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.5.4.881     Document Type: Article

References (19)

1. Young RC: Gynecologic malignancies. In: Cancer Chemotherapy. Pinedo H (ed). Amsterdam, Excerpta Medica pp340-375, 1979.
2. Slayton R, Blessing J and Delago G: Phase II trial of etoposide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Cancer Treatment Rep 66: 1669-1671, 1982.
3. Hoskins PJ, McMurtrie E and Swenerton KD: A phase II trial of intravenous etoposide (VP-16-213) in epithelial ovarian cancer resistant to cisplatin or carboplatin: clinical and serological evidence of activity. Int J Gynecol Cancer 2: 35-40, 1992.
4. Kredentser DC: Etoposide (VP-16), ifosfamide/mesna, and cisplatin chemotherapy for advanced and recurrent carcinoma of the cervix. Gynecol Oncol 43: 145-148, 1991.
5. Pierga J-Y, Dieras V, Paraiso D, Dorval T, Palangie T, Beuzeboc P, Jouve M, Scholl SM, Garcia-Giralt E and Pouilart P: Treatment of advanced or recurrent endometrial carcinoma with combination of etoposide, cisplatin, and 5-fluorouracil: a phase II study. Gynecol Oncol 60: 59-63, 1996.
6. Barlow JJ and Lebe SB: Etoposide (VP-16) plus cisplatin (CDDP): a new active chemotherapeutic combination in patients with stage III - IV ovarian adenocarcinoma. J Surg Oncol 32: 43-45, 1986.
7. Delna M, Lorusso V and Romito S: Cisplatin plus etoposide as second-line treatment in advanced ovarian carcinoma. Cancer Treatment Rep 70: 893-895, 1996.
8. Shiratori O, Kanai H, Uchida N, Takeda Y, Totani T and Sato K: Antitumor activity and toxicity of 254-S, a platinum complex, in rodents. In: Recent Advances in Chemotherapy. Ishigami J (ed). University of Tokyo Press, Tokyo, pp635-636, 1985.
9. Ota K, Wakui A, Majima H, Niitani H, Inuyama Y, Ogawa M, Ariyoshi Y, Yoshida O, Tetsuo T, Kimura I and Kato T: Phase I study of a new platinum complex 254-S, cis-diammine (glycolato)-platinum (II). Jpn J Cancer Chemother 19: 855-861, 1992.
10. Furuse K, Fukuoka M, Asamoto H, Niitani H, Kimura I, Sakuma A and Yamaguchi Y: A randomized comparative study of 254-S plus vindesine (VDS) vs. cisplatin (CDDP) plus VDS in patients with advanced non-small cell lung cancer (NSCLC). Jpn J Cancer Chemother 19: 1019-1026, 1992.
11. Kato T, Nishimura H, Yakushiji M, Noda K, Terashima Y, Takeuchi S, Takamizawa H, Suzuki M, Arai M, Ota M, Tanizawa O, Sekiba K, Hirabayashi K, Yamabe T, Hata T, Akiya K, Sonoda T, Sugawa T, Nagata Y and Hokanishi T: Phase II study of 254-S (cis-diammine glycolato platinum) for gynecological cancer. Jpn J Cancer Chemother 19: 695-701, 1992.
12. Noda K, Takeuchi S, Kurihara S, Sugawa T, Kato T, Ikeda M, Kanazawa K, Tsutsui F, Yamamoto K, Umezu J, Suzuki M, Takamizawa H, Takada M, Akiya K, Hachiya S, Ueda K, Izumi R, Tomoda Y, Ichijyo M, Okada H, Sugimoto O, Mochizuki M, Sekiba K and Yamabe T: Phase II study of cisplatin for cervical and endometrial carcinomas. Jpn J Cancer Chemother 14: 1129-1135, 1987.
13. Noda K, Kato T, Ikeda M, Akiya K, Yajima A, Ueda G, Nishiya I, Takamizawa H, Terashima Y and Tsutsui F: Phase II study of carboplatin in cervical carcinoma. Jpn J Cancer Chemother 15: 3067-3072, 1988.
14. Hirabayashi Y and Okada E: Combination chemotherapy with 254-S, ifosfamide, and peplomycin for advanced or recurrent cervical cancer. Cancer 71: 2769-2775, 1992.
15. Hida S, Okada K and Yoshida O: Advantages in combination chemotherapy using cisplatin and its analogues for human testicular tumor xenografts. Jpn J Cancer Res 81: 425-430, 1990.
16. Nakajima O, Inoue S and Kobayashi K: Differences in intracellular uptake of cisplatin, carboplatin and 254-S among human lung cancer cell lines. Jpn J Lung Cancer 34: 313-319, 1994.
17. Yonei T: Quantitative analysis of in vitro combination effects of platinum analogues and etoposide against human lung cancer cells. Jpn J Lung Cancer 31: 221-227, 1991.
18. Sasaki Y, Ohtsu A, Shimada Y, Ono K and Saijo N: Simultaneous administration of CPT-11 and fluorouracil: alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer. J Natl Cancer Inst 86: 1096-1098, 1994.
19. Sasaki Y: Clinical pharmacology in development of new anticancer agents. Jpn J Cancer Chemother 21: 310-314, 1994.